Skip to content
← Back to this collection

PUBLICATIONS · 19933912

Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
J Clin Oncol
Publication date
2010 Jan 1
First author
Yao JC

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships

    Authors and identifiers

    1. name
      Yao JC
      type
      Author
    2. name
      Lombard-Bohas C
      type
      Author
    3. name
      Baudin E
      type
      Author
    4. name
      Kvols LK
      type
      Author
    5. name
      Rougier P
      type
      Author
    6. name
      Ruszniewski P
      type
      Author
    7. name
      Hoosen S
      type
      Author
    8. name
      St Peter J
      type
      Author
    9. name
      Haas T
      type
      Author
    10. name
      Lebwohl D
      type
      Author
    11. name
      Van Cutsem E
      type
      Author
    12. name
      Kulke MH
      type
      Author
    Complete bibliographic record and source provenance
    authors
    1. name
      Yao JC
      type
      Author
    2. name
      Lombard-Bohas C
      type
      Author
    3. name
      Baudin E
      type
      Author
    4. name
      Kvols LK
      type
      Author
    5. name
      Rougier P
      type
      Author
    6. name
      Ruszniewski P
      type
      Author
    7. name
      Hoosen S
      type
      Author
    8. name
      St Peter J
      type
      Author
    9. name
      Haas T
      type
      Author
    10. name
      Lebwohl D
      type
      Author
    11. name
      Van Cutsem E
      type
      Author
    12. name
      Kulke MH
      type
      Author
    bibliography ids
    1. nci-bib-5dbc68228044793c4a57318d
    book metadata
    content sha256
    5d9bd57bd34570a37249604a6512b8813feb977aed36338ac911df4d09fa1a0c
    document type
    citation
    dois
    1. 10.1200/JCO.2009.24.2669
    electronic publication date
    display
    2009 Nov 23
    precision
    day
    year
    2009
    evidence scope
    bibliographic_metadata_only
    id
    pubmed:19933912
    immutable id
    pubmed:19933912@5d9bd57bd34570a37249604a6512b8813feb977aed36338ac911df4d09fa1a0c
    journal
    abbreviation
    J Clin Oncol
    issn electronic
    1527-7755
    issn print
    0732-183X
    issue
    1
    name
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    nlm unique id
    8309333
    pages
    69-76
    volume
    28
    languages
    1. eng
    notices
    absence is not clearance
    true
    has correction metadata
    false
    has expression of concern metadata
    false
    has retraction in link
    false
    pubmed marks article retracted
    false
    pubmed marks retraction notice
    false
    relationships
      outcomes validated
      false
      pmid
      19933912
      provenance
      batch id
      708c7929ee1eff455330
      provider
      NCBI PubMed ESummary
      record sha256
      0cadea3b912ebae71f67a1707ad21a7a72487b2236249da9a6ec371f56a6a1dc
      response sha256
      d245af3dbc636ffc79325b3798c7bfda16faf0a3d796681b12b8d89bd68eb450
      retrieved at
      2026-09-09T23:46:31.496840+00:00
      publication date
      display
      2010 Jan 1
      precision
      day
      year
      2010
      publication types
      1. Clinical Trial, Phase II
      2. Journal Article
      3. Research Support, Non-U.S. Gov't
      record status
      PubMed - indexed for MEDLINE
      schema version
      1.0
      source url
      https://pubmed.ncbi.nlm.nih.gov/19933912/
      title
      Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial.

      Preserved source evidence · Not medical advice